BIO-Europe Spring EBD Group BIO BIO-Europe Spring
Share:
Email this page Share this on LinkedIn Share this on Twitter | print this page

BIO-Europe Spring® 2014 Program Overview

www.ebdgroup.com/bes/program
Sunday, March 9, 2014
19:30–22:00
Welcome Reception

All BIO-Europe Spring attendees are cordially invited to join us at the National Automobile Museum for a welcome reception. The exhibition will be open until 21:00, exclusively for BIO-Europe Spring attendees.

You will be able to pick up your name badge at the welcome reception.

National Automobile Museum

National Automobile Museum
Corso Unità d'Italia 40
10126 Turin, Italy | (map)

Turin's National Automobile Museum was reopened in 2011 after a large-scale restoration. The exhibition focuses on the history and the evolution of the car, as well as on socio-cultural aspects. Impressive displays of rare and valuable automobiles show the transformation of the car from a means of transport to a cult and design object. The museum has become a landmark for design and industry experts, but is equally attractive for private visitors, students and families.

Sponsored by:

Bioindustry Park Silvano Fumero
Monday, March 10, 2014
07:45
Exhibit Hall
Registration opens
07:45
Exhibit Hall
Exhibition opens and Continental Breakfast
09:00–10:30
Parallel Workshops
Partnering with provider institutions: The new healthcare model?

Monday, 09:00–10:30
Room B

Provider institutions and research hospitals are becoming increasingly more aggressive with their partnering strategies. With access to patients, research, facilities and in some cases manufacturing all under one roof, these providers are altering the traditional healthcare model and attracting collaborations with large pharma and small biotech along the way. Are sponsored research and licensing opportunities truly a fit for both large and small companies alike in working with these institutions? Join the panel as they sit down to discuss the partnering models at work and where the opportunities lie all across the life science ecosystem.

Moderator:
Sarah Haecker – Chief Scientific Officer, Adjuvant Partners

Panelists:
  • Jonathan Beech – Business Development Manager, The Institute of Cancer Research, London
  • Peter de Waele – VP, Research and Development, Cardio 3
  • Angelo Del Favero – General Manager, Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino
  • Ruth McDermott – Commercial Development Manager, Cell Therapy Technologies, GE Healthcare
  • Annastasiah Mudiwa Mhaka – Director of Life Sciences, Business Development and Strategic Alliances, Johns Hopkins Medicine
BIO-Europe Spring® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
Why China matters to your business strategy

Monday, 09:00–10:30
Room E

With the rapidly growing pharma market in China, projected to be number one in the world by 2020, multinational corporations have all established strategies on how to grow and take advantage of this market. But what does that have to do with your pre-market development stage biotech company, that's just trying to meet its next (pre-)clinical milestone? There are vast opportunities for partnering and funding available in China for companies at any development stage. During this workshop, executives from pharma, biotech and venture will provide information on the opportunities available to biotech and give hands-on advice on the essentials in taking your company to China.

Moderator:
Greg B. Scott – President and Founder, ChinaBio® LLC

Panelists:
  • Brian K. Campion – VP, Business Development, RuiYi, Inc
  • Tomas Landh – Director, Strategy and Innovation Sourcing, Diabetes Research Unit, Novo Nordisk
  • Richard Soll – Senior VP, International Discovery Service Unit, WuXi AppTec
  • Li Wang – Director, Academic Alliances, Scientific Partnering and Alliances, Innovative Medicine and Early Development, AstraZeneca
BIO-Europe Spring® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
Due diligence: How to ensure a successful process

Monday, 09:00–10:30
Room C

M&A or partnering agreement, product or technology—a biotech company should be prepared to open its doors, books and personnel to a potential partner for full disclosure. Especially for large deals, due diligence is a complex commercial, legal and financial analysis that involves many within the biotech company and needs to be well orchestrated. Various companies have their own processes in place for how to conduct a thorough due diligence. This workshop will give guidance on what needs to be taken in consideration. How can a biotech company prepare for this process? Who needs to be involved? What is the expectation of timing for what needs to be accomplished? What does the pharma side expect to see and what do they not want to see? Panelists will draw from their due diligence experience and discuss what worked and what did not work so well.

Moderator:
Ben Bonifant – Partner, Triangle Insights Group

Panelists:
  • Sascha Alilovic – Head, Corporate Finance and Corporate Development, MorphoSys AG
  • Jette Asboe Lassen – Director, Business Development, Symphogen A/S
  • John Easton – Head, Business Operations, AstraZeneca Business Development
  • Christian Pangratz – Chief Business Officer, Activaero GmbH
BIO-Europe Spring® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
Reimbursement in European markets

Monday, 09:00–10:30
Room D

Reimbursement regimes in the US and key European markets continue to evolve and "innovate." This includes new and greater use of health technology assessment and related measures ostensibly designed to focus on ensuring that new products are rewarded only insofar as they provide additional therapeutic value. This panel explores both whether changing systems are really working that way, and the growing sharing of experience between payers and value assessment agencies in key markets, including the United States. It will also explore the additional burdens these systems are putting on developers of new products to demonstrate "value."

Moderator:
Joseph Damond – Senior VP, International Affairs, Biotechnology Industry Organization (BIO)

Panelists:
  • Richard C. Ascroft – Senior Director, Corporate Affairs and PRA, Australia, Canada, Europe, Eli Lilly and Company
  • Edith Frénoy – Director, Market Access, EFPIA
  • Alexander Natz – Secretary General, EUCOPE
BIO-Europe Spring® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
10:45–12:30
Welcome and Plenary Session
Opening remarks

Monday, 10:45–11:15
Room A

Speakers:
  • Florian Schoenhammer – Group Managing Director, EBD Group
  • Alessandro Barberis – President, Torino Chamber of Commerce
  • Roberto Cota – President, Regione Piemonte
  • Piero Fassino – Mayor, City of Torino
  • David Thomas – Director of Investment and Policy Research, Biotechnology Industry Organization (BIO)
BIO-Europe Spring® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
Are big biotechs the better dealmakers?

Monday, 11:15–12:30
Room A
 

Moderator:
Barclay James Kamb – Partner, Life Sciences Transactions, Cooley LLP

Panelists:
  • David Colpman – Head of Global Business Development, Shire
  • John F. McDonald – VP, Co-Head, Business Development/M&A, Biogen Idec
  • James Sabry – Senior VP and Global Head, Genentech Partnering, Genentech
  • Jeremy Springhorn – VP, Corporate Development, Alexion Pharmaceuticals, Inc.
BIO-Europe Spring® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
12:30–13:30
Exhibit Hall and Room A
Luncheon
13:30–18:15
Parallel Panel Discussions
Business Development
Dealmaking strategies around orphan diseases

Monday, 13:30–14:30
Room B

Over the last few years, orphan diseases have turned from "do not touch" to everyone's darling. With vast unmet medical needs, improving understanding of diseases, smaller regulatory hurdles and aggressive pricing, both pharma and biotechs see the potential even in indications with very limited patient populations. But are those assumptions right? Do developers of orphan drugs need alliances and collaborations? Or does having a clearly defined and discreet potential market really make it much easier for biotech companies to go it alone all the way from bench to market? What are the advantages/disadvantages of working with big pharma in rare diseases, and what can pharma bring to the table—other than money—that biotechs in the orphan space would want to tap into? Hear from stakeholders who have in some cases succeeded in their ambitions but also bear the battle scars of orphan drug development.

Moderator:
Mike Ward – Global Director of Content, Datamonitor Healthcare & SCRIP Intelligence, Informa

Panelists:
  • Luc Dochez – Chief Business Officer, Prosensa
  • Jeremy Springhorn – VP, Corporate Development, Alexion Pharmaceuticals, Inc.
  • James B. Weissman – Chief Business Officer, Dicerna Pharmaceuticals
BIO-Europe Spring® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
Who will finance early stage drug discovery?

Monday, 14:45–15:45
Room B

Common wisdom holds that it is getting harder and harder to find funding for drug discovery—yet financing data show that private rounds for companies whose lead programs are in preclinical development and earlier have been steadily rising since the meltdown. On top of that, big pharma is increasingly partnering directly with academics on discovery research, as well as participating in regional incubators that support early stage startups. Join a panel of VCs, pharmas and academics as they discuss these different avenues for funding discovery—and the kinds of programs that are attracting investment.

Moderator:
Susan Schaeffer – Editor, BioCentury

Panelists:
  • Daniela Bellomo – Managing Director, TTFactor Srl
  • Jeanne Bolger – VP Venture Investments, Johnson & Johnson Development Corporation
  • Jason Coloma – Global Head, Venture and Innovation, Roche Partnering
  • Graziano Seghezzi – Partner, Sofinnova Partners
  • Ilka Wicke – Director, Investment Manager of the Boehringer-Ingelheim Venture Fund, Boehringer Ingelheim
BIO-Europe Spring® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
Asset-centric companies: Still lean and mean or "so 2012"?

Monday, 16:00–17:00
Room B

During the years of financial drought, new financing structures surfaced in the industry, resulting in lean and asset-centric business models. Among the most popular, the hub and spoke model of building out LLCs around single assets seemed like the model of the future. These capital efficient companies, built for acquisition, promised a faster return to investors. With the IPO window shut for several years, project-based business models seemed like the only viable path to liquidity. But in the current financial climate, are these companies set up too narrowly to take advantage of the upswing in public markets? Is it time to loosen the belt and build companies again? Or was the change of dynamics among life science players long overdue and will outlast the financial uptake? Is it foolish to build biotechs in any particular way that's designed to take advantage of a high-point or low-point in what is obviously a cyclical market? Or how can you build in enough flexibility so your companies are suited to any stage of the cycle? Join us as biotech CEOs and VCs weigh in.

Moderator:
John Hodgson – Editor, SCRIP Intelligence

Panelists:
  • Francesco De Rubertis – Partner, Index Ventures
  • Shaun K. Hawkins – VP, New Ventures, Eli Lilly and Company
  • Bimal R. Shah – VP, Corporate and Business Development, Spectrum Pharmaceuticals, Inc.
  • Simon Westbrook – CEO, Levicept Ltd.
BIO-Europe Spring® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
Go big or go home: When to go against the trends in R&D and dealmaking

Monday, 17:15–18:15
Room B

Every pharma company boasts about being innovation-driven, yet most of their R&D targets and approaches are the same. Is there an R&D 'fashion victim syndrome' that makes everyone invest in the same spaces? Who is preventing true innovation? Company boards? The regulators? Ourselves? Sit down with executives from pharma to discuss why going into unpopular areas alone can actually be wildly successful.

Moderator:
Carlos de Sousa – Chief Business Officer, to-BBB

Panelists:
  • Philippe Lopes-Fernandes – Senior VP and Head, Global Licensing and Business Development, EMD Serono
  • Benoît Palms – Head of Licensing, Licensing and Corporate Development, Almirall
  • Christoph Pittius – VP, Head of Transactions, Business Development, AstraZeneca
  • Corinne Savill – Head, Business Development and Licensing, Novartis
BIO-Europe Spring® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
In the Spotlight
Non-dilutive financing options

Monday, 13:30–14:30
Room D

There is more than one way to fund new companies and today more than ever CEOs and entrepreneurs are considering a variety of different sources of capital to fund discovery and early development. This workshop will examine how biotechnology companies can best identify, approach, and capture non-dilutive capital from various groups as part of their commercialization objectives. The panel will provide an understanding of funding and procurement opportunities and will discuss how biotechnology companies must communicate the advantages and the state of development of their technology so that it resonates most effectively with funding and purchasing decision makers.

Moderator:
Sinclair Dunlop – Managing Partner, Epidarex Capital

Panelists:
  • Matthew Durdy – Chief Business Officer, Cell Therapy Catapult
  • Steve Ford – CEO, Parkinson's UK
  • Michael Sullivan – Lead Technologist, Regenerative Medicine, Technology Strategy Board
  • Mark Velleca – Executive VP, Chief Policy and Advocacy Officer, The Leukemia & Lymphoma Society
BIO-Europe Spring® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
The personalized therapy challenge: How can therapeutic developers incorporate a biomarker strategy that enhances rather than limits the commercial opportunity?

Monday, 14:45–15:45
Room D

Very few companies have the in-house expertise to understand and identify all of the relevant biomarkers relating to a specific disease target or new therapeutic opportunity. These insights will likely come through external collaborations. One of the key questions facing drug developers today is how to incorporate efficient use of biomarkers into a drug development and clinical program that will help them validate a commercial opportunity. The companion diagnostics they will need as part of these programs could be developed by academic institutions or small Dx companies or more established Dx companies such as Qiagen or Ventana. This panel will consider the partnering options available to oncology companies and other therapeutic developers as they seek to identify and acquire access to biomarkers that will be key to their commercial success.

Moderator:
Linda Pullan – President, Pullan Consulting

Panelists:
  • Lori L. Badura – Director, Search and Evaluation, Global Licensing and Business Development, EMD Serono
  • Eric B. Dahlhauser – CEO, Insight Genetics, Inc.
  • Leonie de Best – COO, SkylineDx
  • Ferran Prat – VP, Strategic Industry Ventures, MD Anderson Cancer Center
  • Cecilia Schott – Head Personalized Healthcare, Corporate Development and Ventures, AstraZeneca
BIO-Europe Spring® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
Gene therapy and gene modified cell therapies: What are the collaborative models and partnerships that will enable successful commercialization of these products?

Monday, 16:00–17:00
Room D

The burgeoning interest in gene therapy is evidenced by a large number of new companies being formed in the sector, pharma investment in a variety of gene therapy programs, and the growing interest in gene-modified therapies to harness the immune system in the treatment of cancer and other diseases. While most stakeholders acknowledge that gene therapy is fundamentally more complex than most other biologics due to the need to create a virus safely at scale and to then transport those viruses efficiently and safely, many companies believe these issues can be addressed as long as the clinical results are compelling. This session will examine the types of unique partnerships that will be required to support successful development of gene therapy products and some of the differences between treating monogenic disorders vs. more complex diseases with diverse disease populations.

Moderator:
Robert A. Preti – President and Chief Scientific Officer, Progenitor Cell Therapy

Panelists:
  • Zami Aberman – Chairman and CEO, Pluristem
  • Gregory MacMichael – Global Head of Advanced Therapies, Technology Research and Development, Novartis
  • Peter Nolan – Executive Director, Senior VP, Commercial Development, Oxford BioMedica
  • Philip G. Vanek – GM Cell BioProcessing, GE Healthcare
BIO-Europe Spring® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
Final exams: When academic science is called on to prove its value

Monday, 17:15–18:15
Room D

The recent resurgence in both Europe and the United States in early stage activity in biotech has raised interest in the role of technology transfer offices. Most TTOs serve as repositories of practical and institutional wisdom for both researchers wanting to see their work commercialized and for pharmaceutical and biotechnology companies interested in licensing it. But since much of the recent investment interest in the early stage has come from family offices, angel investors, superangels and "accelerator" funds, TTOs have had to step up and serve a more diverse constituency over a longer time span and in a more active way. How are TTOs coping with these new challenges? Has the recent revelation that a large percentage of academic work is difficult to reproduce raised the bar for licensing and company formation? Are more researchers seeking company affiliations and licensing deals? What are some differences in the way that European and US TTOs do their work?

Moderator:
Werner Lanthaler – CEO, Evotec

Panelists:
  • Diane Harbison – Head of Business Development, Edinburgh BioQuarter, University of Edinburgh
  • Francesca Pasinelli – General Manager, Fondazione Telethon
  • Chris Stahl – Business Development Manager, Center for Technology Commercialization, Cincinnati Children's Hospital Medical Center
BIO-Europe Spring® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
Therapeutic Insight 2014


Therapeutic Insight by Defined Health
Industry panel: Pharma steps up early on relevance data

Industry panel: Pharma steps up early on relevance data
Monday, 13:30–14:30
Room E

When it comes to valuations on biotech/pharma deals, one principle has historically been inviolate: later stage programs, especially those having demonstrated clinical proof-of-concept, are typically worth substantially more than pre-PoC programs to pharma buyers. The good news for biotech is that the last two years have seen close to a 180-degree turn away from PoC as a valuation driver.

Put simply, pharma is not buying late nearly as often as they have done in the past, and when they do, they are paying less. Clinical stage deal values, having reached a peak in 2012, are showing annual declines both in terms of upfront payments and total deal size. Meanwhile, valuations on pre-clinical stage deals have spiked, beginning in 2012 and continuing through 2013. Importantly, upfront payments on these early deals have also increased, even though the inventory of available preclinical programs is actually greater than that for clinical stage assets.

Proof of Relevance (PoR), a term first coined by Defined Health in 2009, has now nearly displaced PoC as the primary valuation driver for deals across all discovery and development stages. Put bluntly, too many of today's "available" clinical stage programs have become therapeutically and/or pharmacoeconomically irrelevant. The good news for developers, investors and prospective partners is that PoR can be achieved prior to (very often long before) PoC, and on a lot less invested capital.

But what type of data confers PoR and moves an early stage company to the front of the queue? This panel, comprising both pharma and biotechs involved with lucrative early stage transactions, will discuss recipes for the "secret sauce" that confers PoR on a program and/or platform and thus and separates successful early stage sellers from the rest.

Moderator:
Ed Saltzman – President and Founder, Defined Health

Panelists:
  • Susan Herbert – Executive VP, Global Business Development and Strategy, Merck Serono
  • John F. McDonald – VP, Co-Head, Business Development/M&A, Biogen Idec
  • James Sabry – Senior VP and Global Head, Genentech Partnering, Genentech
  • Dieter Ziegler – Director, Ventures and Early Stage Collaborations, AbbVie
BIO-Europe Spring® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
Addressing cognitive deficits across CNS disorders: Potential to improve overall functional outcomes and QoL

Addressing cognitive deficits across CNS disorders: Potential to improve overall functional outcomes and QoL
Monday, 14:45–15:45
Room E

Treatments for psychiatric disorders focus largely on mood/emotion, and those for neurological disorders on motor function; however, poorly controlled cognitive deficits are equally prominent and severely compromise functional outcomes and quality of life in diseases such as schizophrenia, Huntington's disease, Parkinson's disease and depression.

Cognitive dysfunction does not simply signify poor memory—the range of cognitive impairment is broader and more complex, with domains ranging from executive function to visual memory to attention and/or vigilance.

Cognitive dysfunction cuts across traditional boundaries of diagnoses, presenting challenges to defining and characterizing these deficits. Likewise, determining which cognitive domains are affected in diagnostically discrete disorders is complicated by co-morbidities. Nonetheless, certain cognitive domains can be perturbed in several distinct disorders. Assuming that similar mechanisms are involved, a drug that improves executive function, for example, could be active across several disorders in which this domain is impaired.

Moderator:
Ginger S. Johnson – VP, Defined Health

Panelists:
  • Jamie L. Eberling – Senior Associate Director, Research Programs, The Michael J. Fox Foundation
  • Dana C. Hilt – Senior VP, Clinical Development and Chief Medical Officer, EnVivo Pharmaceuticals
  • Malcolm Weir – Founder, Director and CEO, Heptares
BIO-Europe Spring® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
Autoimmune disease: Finding early differentiation in crowded markets

Autoimmune disease: Finding early differentiation in crowded markets
Monday, 16:00–17:00
Room E

Humira is currently the top selling pharmaceutical in the world and represents just one of eight approved targeted therapies for RA, a market with an estimated prevalence of less than USD 5 million in the seven major pharmaceutical markets. Rheumatoid arthritis, as well as many of the other indications in which anti-TNFs are entrenched, has all the hallmarks of a mature market (including biosimilars on the horizon), and many view the market as overcrowded. However, significant unmet medical needs remain in RA, where approximately 1/3 of patients are not achieving a 20% improvement in symptoms on biologics, and needs are even greater in other indications such as IBD. Within this setting, developers of early stage programs are struggling to differentiate their programs and to choose the appropriate indication and path forward for clinical development.

Our panel will discuss the challenges associated with differentiating products at early stages of development in autoimmune disease, and potential strategies for choosing lead indications and demonstrating proof-of-relevance to potential partners and/or investors, as well as patients and payers.

Moderator:
Aileen Nicoletti – VP, Defined Health

Panelists:
  • Ian Anderson – VP, Immunology Scientific Innovation, Immunology, Janssen R&D, Johnson & Johnson Innovation
  • Mike Crowley – Director, Business Development, Genentech Partnering, Genentech
  • Anand Gautam – Director, Biopharm Innovation Sourcing, Novo Nordisk
  • Andre Hoekema – Senior VP Corporate Development, Galapagos
  • Arndt Schottelius – Chief Development Officer, MorphoSys AG
BIO-Europe Spring® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
From pariah to darling: Biopharma finally courts immunotherapies

From pariah to darling: Biopharma finally courts immunotherapies
Monday, 17:15–18:15
Room E

Immuno-oncology is suddenly the most talked about approach for changing the treatment paradigm of cancer, though a few short years ago almost no large biopharma wanted to touch these programs. Of course, one or two successes can change the fates (and funding and partnering chances) of the many. And yet the two exemplars, Provenge and Yervoy, stand worlds apart. The excitement in the space is being further fueled by advancing science, such as strong data on the PD-1 inhibitors, and dealmaking, such as the recent Roche and immatics partnership. This panel will discuss this new and powerful approach, getting into the important differences between platforms in terms of scientific risk, clinical development strategies and commercial challenges. The discussion will also place these programs in the context of other competing approaches (e.g., anti-CD19 CAR T cells vs. anti-CD19 monoclonal antibodies) and the evolving pharmaco-economics of oncology.

Moderator:
Jeffrey M. Bockman – VP, Defined Health

Panelists:
  • Paul G. Higham – CEO, immatics biotechnologies
  • Axel Hoos – VP, Oncology R&D, DPU Head, Immuno-Oncology and Combinations, GlaxoSmithKline
  • Hy Levitsky – Global Head, Cancer Immunology Experimental Medicine, Pharma Research and Early Development, Roche
  • Myra Patchen – Chief Scientific Officer, Biothera
BIO-Europe Spring® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
Pharma Presentations
Novartis Pharma

Novartis Pharma
Monday, 13:45–14:00
Room C

Speaker:
  • Charles Bailey – Head of Search and Evaluation Neuroscience
BIO-Europe Spring® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
Johnson & Johnson Innovation

Johnson & Johnson Innovation
Monday, 14:00–14:15
Room C

Speaker:
  • Johan Verbeeck – Senior Director, Partnership Management
BIO-Europe Spring® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
14:15–14:30
Pfizer

Pfizer
Monday, 14:15–14:30
Room C

Speaker:
  • James Eshelby – Senior Director, Worldwide Business Development
BIO-Europe Spring® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
14:30–14:45
Amgen

Amgen
Monday, 14:30–14:45
Room C

Speaker:
  • John O'Connor – Executive Director
BIO-Europe Spring® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
14:45–15:00
AstraZeneca

AstraZeneca
Monday, 14:45–15:00
Room C

Speaker:
  • Jeanette Evans – Director, Corporate Strategy
BIO-Europe Spring® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
Takeda Pharmaceutical Company Ltd.

Takeda Pharmaceutical Company Ltd.
Monday, 15:00–15:15
Room C

Speaker:
  • Ian Moules – Senior Director Search and Evaluation
BIO-Europe Spring® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
15:15–15:30
AbbVie

AbbVie
Monday, 15:15–15:30
Room C

Speaker:
  • John Poulos – VP, Head of Licensing and Acquisitions
BIO-Europe Spring® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
15:30–15:45
Merck Serono

Merck Serono
Monday, 15:30–15:45
Room C

Speaker:
  • Susan Herbert – Executive VP, Global Business Development and Strategy
BIO-Europe Spring® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
15:45–16:00
Novo Nordisk

Novo Nordisk
Monday, 15:45–16:00
Room C

Speaker:
  • Tomas Landh – Director, Strategy and Innovation Sourcing
BIO-Europe Spring® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
Shire Pharmaceuticals

Shire Pharmaceuticals
Monday, 16:00–16:15
Room C

Speaker:
  • Naina Bhasin – Director, Scientific Licensing, Business Development
BIO-Europe Spring® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
Alexion Pharmaceuticals

Alexion Pharmaceuticals
Monday, 16:15–16:30
Room C

Speaker:
  • Jeremy Springhorn – VP, Corporate Development
BIO-Europe Spring® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
16:30–16:45
Roche

Roche
Monday, 16:30–16:45
Room C

Speaker:
  • Stefan Frings – Head of Oncology, Immuno-Oncology Partnering
BIO-Europe Spring® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
16:45–17:00
Genentech

Genentech
Monday, 16:45–17:00
Room C

Speaker:
  • Angele Maki – Senior Manager, Genentech Partnering
BIO-Europe Spring® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
13:30–18:30
One-to-one Meetings ►
18:00–18:30
Exhibit Hall Hospitality Reception

partnering360 Join us at booth #24 and learn how the industry's largest network of life science professionals can increase your business opportunities.

Hosted by:

EBD Group partnering360
19:00
Evening Networking Reception
Teatro Regio Teatro Regio

Teatro Regio
Piazza Castello, 215
10124, Turin, Italy | (map)

Teatro Regio was established in 1740 as the theatre of the Savoy court. From the era of Toscanini and Puccini in the 19th century to ballet, opera and symphony concerts today, it is one of the most productive cultural centers of the region. After burning down it was rebuilt in today's magnificent curvilinear design, with one of the largest stages in Europe and advanced technology for the staging of particularly complex productions.

Venue provided by:
The Regional Host Committee

18:30–19:00 Shuttle buses will transport guests to the evening event
21:30–22:30 Shuttle buses will transport guests to conference hotels
 Estimated travel time is 20-30 minutes (City Center Turin)

Tuesday, March 11, 2014
07:45
Exhibit Hall
Registration opens
07:45
Exhibit Hall
Exhibition opens and Continental Breakfast
09:00–13:00
Company Presentations ►
08:00–18:30
One-to-one Meetings ►
11:30–12:40
Room C
Academic Innovators™ Showcase

Join us for the Academic Innovators™ presentation track as we work with industry leaders to shine a spotlight on the many scientific advances with strong translational potential being made in the academic world.

Academic Innovators™ Presentations by:
  • Cincinnati Children's Hospital Medical Center
  • Edinburgh BioQuarter
  • Fondazione Istituto Italiano di Tecnologia
  • Jagiellonian University
  • MicroMarine Biotech - Universidad de Valparaíso
  • TTFactor srl
  • University of Trieste - Department of Life Sciences
13:00–14:00
Exhibit Hall and Room A
Luncheon
14:00–15:00
BioInItaly Report 2014: The Italian Biotech Sector

Tuesday, 14:00–15:00
Room B

Ernst & Young will preview the results of their latest surveys on Italian biotech companies. The facts include increased turnover, a steady number of companies and even a higher investment rate in research. Assobiotec, the Italian Bioindustry Association, will comment.

Speakers:
BioInItaly Report 2014: Facts and figures
  • Antonio Irione – Partner, Ernst & Young
The industry point of view
  • Alessandro Sidoli – President, Assobiotec
BIO-Europe Spring® 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
14:00–18:00
Company Presentations ►
17:45–18:45
Exhibit Hall Hospitality Receptions

Hosted by:

Boehringer Ingelheim Boehringer Ingelheim Hessen Trade and Invest Hessen Trade and Invest
Lonza Lonza The Regional Host Committee The Regional Host Committee
19:00
Evening Networking Reception
The Palace of Venaria The Palace of Venaria

The Palace of Venaria
Piazza della Repubblica, 4
10078 Venaria Reale
Turin, Italy | (map)

The Palace of Venaria is a former residence of the Royal House of Savoy located in Venaria Reale, six miles from the city center of Turin. It was designed and built beginning in 1675, with extensive restorations in the last few decades, including the magnificent gardens. The Palace was included in the UNESCO Heritage List in 1997, and is one of the largest royal residences in the world.

Venue provided by:
The Regional Host Committee

18:30–19:00 Shuttle buses will transport guests to the evening event
21:30–22:30 Shuttle buses will transport guests to conference hotels
 Estimated travel time is 30-40 minutes

Wednesday, March 12, 2014
07:45
Exhibit Hall
Registration opens
07:45
Exhibit Hall
Exhibition opens and Continental Breakfast
09:00–13:00
Company Presentations ►
08:00–17:00
One-to-one Meetings ►
13:00–14:00
Exhibit Hall and Room A
Luncheon
16:30
Closing Reception
Arrow Up


© 2009–2014 EBD GmbH
BIO-Europe Spring EBD Group BIO BIO-Europe Spring